New immune therapy combo shows promise for tough transplant complication
NCT ID NCT01937468
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 22 times
Summary
This early-phase trial tests the safety of combining donor anti-inflammatory Treg cells with low-dose interleukin-2 (IL-2) for people with chronic graft-versus-host disease (cGVHD) that hasn't responded to steroids. cGVHD is a condition where the donor's immune cells attack the recipient's body after a stem cell transplant. The study involves 25 participants and aims to find the safest dose and check for side effects, with the goal of controlling the disease rather than curing it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VERSUS HOST DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Insitute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.